Treatment of Advanced Bladder Cancer with Cis-Diamminedichloroplatinum (II NSC 119875): A Pilot Study

Publisher Website
Google Scholar
Abstract
A pilot study was done using 19 patients with bladder cancer to test the efficacy of cis-diamminedichloroplatinum as a single agent to treat transitional cell carcinoma. Fourteen patients had stage D lesions, 3 patients had stage C and 2 patients had stage B tumors. The patients received 1 mg/kg cis-diamminedichloroplatinum mixed with 2000 cc 5% dextrose in 1/3 normal saline solution, 37.5 gm mannitol and 40 mEq potassium chloride. The mixture was given in a slow infusion lasting 6-8 h every week for the first 6 wk and every 3 wk thereafter. In patients with stage D disease 1 complete clinical remission, 7 partial clinical remissions, 1 minimal objective response and 1 subjective response were observed. Four patients did not respond to treatment. In the 3 stage C patients no response to the drug was observed. In the stage B patients 1 partial remission and 1 minimal objective response were seen. A total objective response (complete and partial remissions) was seen in 9 of the 19 patients (47%). The duration of the responses varied from 2-10 mo. with an average of 4.8 mo. These promising results seem to indicate the high degree of effectiveness of cis-diamminedichloroplatinum against transitional cell carcinoma of the bladder.